The FDA has approved updated Covid-19 vaccines from Pfizer and Moderna targeting the KP.2 variant for an autumn vaccination drive. These vaccines are expected to provide better protection against severe symptoms of circulating variants. The shots for children below 12 years are cleared under the agency's emergency use authorization pathway. Novavax's protein-based vaccine is still under review.